Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells.
Thamir M MahgoubEmmet J JordanAmira F MahdiVeronika OettlStefanie HuefnerNorma O'DonovanJohn CrownDenis M CollinsPublished in: Cancer chemotherapy and pharmacology (2024)
Our study confirms that ABT-751 is active against melanoma cell lines and models of MDR at physiologically relevant concentrations, it inhibits P-gp ATPase activity, and it may be a BCRP and/or MDR3 substrate. ABT-751 warrants further investigation alone or in tandem with other drug efflux transporter inhibitors for hard-to-treat MDR melanoma.